Serial-X | SERIAL CRYSTALLOGRAPHY SOLUTIONS FOR SYNCHROTRON RADIATION FACILITIES

Summary
Serial-X aims to expand of the use of serial crystallography across the academic and industrial life-science community by introducing low cost, flexible and easy to use solutions to the most common problems that occur in serial crystallography experiments today. Serial crystallography is a developing method of macromolecular X-ray crystallography that allows diffraction data to be collected at room temperature from a continuous stream of microcrystals. “ProtonPump”, the ERC Advanced Grant awarded to Richard Neutze, applies time-resolved serial crystallography to observe structural changes that occur during the reduction of molecular oxygen to water by cytochrome c oxidase. This PoC builds directly from technical solutions developed to achieve the scientific goals of “ProtonPump”. Serial crystallography was first developed at an X-ray free electron laser but is increasingly being used at synchrotron radiation facilities. Synchrotrons can potentially support up to two orders of magnitude more serial crystallography users than X-ray free electron lasers. Synchrotron based serial crystallography experiments may also become a mainstream method in structure-based-drug-design. But these possibilities will not be realized if the current lack of standardization in sample delivery continues, which is currently prohibitively expensive and requires a high level of technical support to operate. Serial-X will solve this problem by developing and bringing to market standardized, low-cost, flexible and easy-to-use solutions for sample delivery in serial crystallography studies at synchrotron radiation sources. Serial-X will thereby remove the greatest obstacle currently preventing scientists from using serial crystallography for their own research or for structure based drug-design within a pharmaceutical drug discovery context. A spin off company will be formed to manufacture and distribute the technologies developed within this Proof of Concept Grant.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/963936
Start date: 01-11-2020
End date: 30-04-2022
Total budget - Public funding: - 150 000,00 Euro
Cordis data

Original description

Serial-X aims to expand of the use of serial crystallography across the academic and industrial life-science community by introducing low cost, flexible and easy to use solutions to the most common problems that occur in serial crystallography experiments today. Serial crystallography is a developing method of macromolecular X-ray crystallography that allows diffraction data to be collected at room temperature from a continuous stream of microcrystals. “ProtonPump”, the ERC Advanced Grant awarded to Richard Neutze, applies time-resolved serial crystallography to observe structural changes that occur during the reduction of molecular oxygen to water by cytochrome c oxidase. This PoC builds directly from technical solutions developed to achieve the scientific goals of “ProtonPump”. Serial crystallography was first developed at an X-ray free electron laser but is increasingly being used at synchrotron radiation facilities. Synchrotrons can potentially support up to two orders of magnitude more serial crystallography users than X-ray free electron lasers. Synchrotron based serial crystallography experiments may also become a mainstream method in structure-based-drug-design. But these possibilities will not be realized if the current lack of standardization in sample delivery continues, which is currently prohibitively expensive and requires a high level of technical support to operate. Serial-X will solve this problem by developing and bringing to market standardized, low-cost, flexible and easy-to-use solutions for sample delivery in serial crystallography studies at synchrotron radiation sources. Serial-X will thereby remove the greatest obstacle currently preventing scientists from using serial crystallography for their own research or for structure based drug-design within a pharmaceutical drug discovery context. A spin off company will be formed to manufacture and distribute the technologies developed within this Proof of Concept Grant.

Status

CLOSED

Call topic

ERC-2020-POC

Update Date

27-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.1. EXCELLENT SCIENCE - European Research Council (ERC)
ERC-2020
ERC-2020-PoC